Compare Heron Therapeutics Inc (HRTX) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs UnitedHealth Group Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while UnitedHealth Group Inc trades at $421.62 (market cap $382.83B). The key difference: UnitedHealth Group Inc is far larger — about 4185.8× Heron Therapeutics Inc's market cap, and UnitedHealth Group Inc pays a 2.2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | UNH | |
|---|---|---|
Market Cap | $91.46M | $382.83B |
Sector | Health | Health |
52-Week High | $1.96 | $431.68 |
52-Week Low | $0.39 | $237.77 |
Enterprise Value | $189.36M | $429.52B |
Dividend Yield | — | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
UnitedHealth Group (UNH) trades at $421.55, down 1.07% today, with strong bullish technical signals and consistent earnings beats. Revenue reached $447.57B in 2025, though net margins compressed to 2.68%. The company maintains robust cash flow from operations at $19.70B and announced a $2.32 dividend for H1 2026. Recent news highlights strategic moves to reduce pediatric prior authorizations, aiming to improve care access and operational efficiency.
Outlook remains positive with analyst consensus targeting $466.41, representing ~11% upside. Key opportunities include aging demographics and tech-driven healthcare adoption. Risks involve regulatory scrutiny, as seen in Massachusetts' Medicaid lawsuit, and margin pressure from rising costs. Institutional sentiment is strongly bullish with 82.7% buy ratings, supporting long-term growth prospects amid sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
